Survival curves for high-risk DLBCL patients treated with atezolizumab consolidation. Disease free survival (A) and overall survival (B) outcomes observed in 109 patients diagnosed with high-risk DLBCL who achieved complete remission and were treated with atezolizumab for up to 54 weeks.